CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment (SAC-COVID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04317040|
Recruitment Status : Active, not recruiting
First Posted : March 20, 2020
Last Update Posted : September 25, 2020
The study is designed as a randomized, placebo-controlled, double blind, multicenter, Phase III trial to compare two COVID-19 treatment regimens in hospitalized adult subjects who are diagnosed with severe and critical COVID 19.
Arm A: CD24Fc/Best Available Treatment; Arm B: placebo/ Best Available Treatment. CD24Fc will be administered as single dose of 480 mg via IV infusion on Day 1. Total of 270 subjects will be enrolled and randomized in 1:1 ratio to receive CD24Fc or placebo. All subjects will be treated with the best available treatment. The follow up period is 28 days.
|Condition or disease||Intervention/treatment||Phase|
|Covid19||Drug: CD24Fc Drug: Placebo||Phase 3|
As the newest global medical emergency, the COVID-19 (diagnosed SARS-CoV2 infection with lung involvement) exhibits features that are unlikely ameliorated by antivirals-based approaches alone. First, although the new coronavirus (SARS-CoV-2) infect lung and intestine, many patients suddenly take a turn for the worse even when the viral replication appears to be under control. Second, patients with serious or critical clinical symptoms show remarked T cell lymphopenia that are more severe and more acute than human immunodeficiency virus (HIV) infection. Functional exhaustion of T cells is suggested by high expression of T-cell exhaustion markers, which again appears more acute than in HIV patients. Third, multiple cytokines are elevated among patients with severe clinical symptoms, which potentially explains the multiple organ failure associated with COVID-19. For these reasons, treatment of COVID-19 likely requires a combination of both antivirals and non-antivirals-based approaches.
CD24Fc is a biological immunomodulator in Phase II/III clinical trial stage. CD24Fc comprises the nonpolymorphic regions of CD24 attached to the Fc region of human IgG1. We have shown that CD24 is an innate checkpoint against the inflammatory response to tissue injuries or danger-associated molecular patterns (DAMPs). Preclinical and clinical studies have demonstrated that CD24Fc effectively address the major challenges associated with COVID-19. First, a Phase I clinical trial on healthy volunteers not only demonstrated safety of CD24Fc, but also demonstrated its biological activity in suppressing expression of multiple inflammatory cytokines. Second, in Phase II clinical trial in leukemia patients undergoing hematopoietic stem cell transplantation (HCT), three doses of CD24Fc effectively eliminated severe (Grade 3-4) acute graft vs host diseases (GVHD), which is caused by over reacting immune system and transplanted T cells attacking recipient target tissues. Third, in preclinical models of HIV/SIV infections, we have shown that CD24Fc ameliorated production of multiple inflammatory cytokines, reversed the loss of T lymphocytes as well as functional T cell exhaustion and reduced the leukocyte infiltration of multiple organs. It is particularly noteworthy that CD24Fc reduced the rate of pneumonia in SIV-infected Chinese rhesus monkey from 83% to 33%. Therefore, CD24Fc maybe a prime candidate for non-antiviral biological modifier for COVID-19 therapy. The phase III trial will involve 270 patients randomized into blinded placebo and CD24Fc arms, with time to clinical improvement from critical or severe to mild symptom as the primary endpoint.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||241 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment|
|Actual Study Start Date :||April 8, 2020|
|Estimated Primary Completion Date :||October 31, 2020|
|Estimated Study Completion Date :||December 2020|
Experimental: CD24Fc Treatment
Single dose at Day 1, CD24Fc, 480mg, diluted to 100ml with normal saline, IV infusion in 60 minutes.
CD24Fc is given on Day 1.
Other Name: Human CD24 and human IgG Fc Fusion Protein
Placebo Comparator: Placebo
Single dose at Day 1, normal saline solution 100ml, IV infusion in 60 minutes.
Placebo is given on Day 1.
Other Name: Saline
- Improvement of COVID-19 disease status [ Time Frame: 29 days ]Time to improve in clinical status: the time (days) required from the start of treatment to the improvement of clinical status "severe" to "moderate/mild"; or improvement from "scale 2, 3, or 4" to "scale 5 or higher" based on NIAID ordinal scales.
- Proportion of patients who died or had respiratory failure. [ Time Frame: 29 days ]Proportion of patients who died or had respiratory failure, defined as the need for mechanical ventilation, ECMO, non-invasive ventilation, or high flow oxygen devices, at Day 29
- Disease progression of COVID-19 [ Time Frame: 29 days ]Time for disease progression from NIAID scale 3 or 4 to need to be on invasive mechanical ventilation, or ESMO, or death, or from NIAID scale 2 to death.
- All cause of death [ Time Frame: 15 days and 29 days ]All cause of death
- Proportion of clinical relapse [ Time Frame: 29 days ]Proportion of clinical relapse, as defined by rate of return to oxygen support for more than 1 day within 29 days from randomization after initial recovery
- Conversion rate of clinical status at Day 8 [ Time Frame: 8 days ]Conversion rate of clinical status on days 8 (proportion of subjects who changed from NIAID ordinal "scale 3 or 4" to "scale 5 or higher")
- Conversion rate of clinical status at Day 15 [ Time Frame: 15 days ]Conversion rate of clinical status on days 15 (proportion of subjects who changed from NIAID ordinal "scale 3 or 4" to "scale 5 or higher")
- Hospital discharge time [ Time Frame: 29 days ]The discharge time, calculated after the randomization.
- Duration of mechanical ventilation [ Time Frame: 29 days ]Duration of mechanical ventilation (IMV, NIV) (days)
- Duration of pressors [ Time Frame: 29 days ]Duration of pressors (days)
- Duration of ECMO [ Time Frame: 29 days ]Duration of extracorporeal membrane oxygenation (days)
- Duration of high flow oxygen therapy [ Time Frame: 29 days ]Duration of oxygen therapy (oxygen inhalation by high flow nasal cannula or mask) (days)
- Absolute lymphocyte count [ Time Frame: 29 days ]Changes of absolute lymphocyte count in peripheral blood
- Change of D-dimers [ Time Frame: 15 and 29 days ]The changes of plasma concentration of D-dimers
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04317040
|United States, Florida|
|Baptist Health Research Institute|
|Jacksonville, Florida, United States, 32207|
|United States, Maryland|
|Anne Anundel Medical Center|
|Annapolis, Maryland, United States, 21401|
|Institute of Human Virology, University of Maryland Baltimore|
|Baltimore, Maryland, United States, 21201|
|Shady Grove Medical Center|
|Rockville, Maryland, United States, 20850|
|White Oak Medical Center|
|Silver Spring, Maryland, United States, 20904|
|United States, Michigan|
|Henry Ford Health System|
|Detroit, Michigan, United States, 48202|
|United States, Nevada|
|University Medical Center of Southern Nevada|
|Las Vegas, Nevada, United States, 89102|
|United States, New Jersey|
|Cooper University Hospital|
|Camden, New Jersey, United States, 08103|
|Atlantic Health System|
|Morristown, New Jersey, United States, 07960|
|United States, Ohio|
|The Christ Hospital|
|Cincinnati, Ohio, United States, 45219|
|University Hospitals of Cleveland|
|Cleveland, Ohio, United States, 44106|
|The Ohio State University Medical Center|
|Columbus, Ohio, United States, 43210|
|United States, Texas|
|University of Texas at Houston|
|Houston, Texas, United States, 77030|
|Study Director:||Pan Zheng, MD, PhD||OncoImmune, Inc.|